Connect with us
DAPA Banner

Business

Glaukos Stock Surges 18% on Record Q1 Sales Beat and Raised 2026 Outlook as iDose TR Demand Soars

Published

on

FTSE 100 Surges 0.8% Today as Oil Eases and Markets

ALISO VIEJO, Calif. — Glaukos Corp. shares jumped more than 17% Thursday, climbing to $137.49 in morning trading after the ophthalmic medical technology company posted record first-quarter sales that crushed expectations and raised its full-year 2026 revenue guidance, driven by explosive adoption of its iDose TR glaucoma implant.

The company reported net sales of $150.6 million for the quarter ended March 31, a 41% increase from the year-ago period on a reported basis and 39% on a constant-currency basis. The results far exceeded Wall Street forecasts around $137 million, marking another strong quarter for the glaucoma-focused innovator.

U.S. glaucoma sales led the charge, reaching a record $93.5 million, up 58% year-over-year. International glaucoma revenue added $35.8 million, rising 23% on a reported basis. The iDose TR, Glaukos’ groundbreaking dropless, long-duration intracameral implant that continuously delivers glaucoma medication, contributed approximately $54 million in the quarter as physician and patient uptake accelerated.

“This performance reflects strong execution across our commercial and development priorities,” CEO Thomas Burns said in the earnings release. “Our teams continue to demonstrate the strength of our differentiating technology platforms as we advance as an increasingly diversified leader in ophthalmology.”

Advertisement

Investors rewarded the outperformance and forward-looking optimism. Glaukos raised its full-year 2026 net sales guidance to $620 million to $635 million, up from the previous range of $600 million to $620 million. The update signals confidence in sustained momentum for iDose TR and the broader glaucoma franchise.

The stock’s surge came on heavy volume as traders reacted to the beat-and-raise report released after the market close Wednesday. Shares had traded around $117 before the move, reflecting renewed enthusiasm for Glaukos’ interventional ophthalmology strategy.

Glaukos specializes in minimally invasive glaucoma surgery devices and novel pharmaceutical therapies. Its iStent family of micro-bypass implants and the newer iDose TR aim to reduce or eliminate the need for daily eye drops, addressing a major challenge in glaucoma management where patient non-compliance often leads to disease progression.

Gross margin performance remained robust. GAAP gross margin stood at approximately 78%, while non-GAAP gross margin reached about 84%, up 120 basis points year-over-year. The company reported a GAAP net loss of $19.8 million, or 34 cents per share, and a non-GAAP net loss of $10.4 million, or 18 cents per share — both better than expected.

Advertisement

Glaukos ended the quarter with a strong balance sheet: $280.5 million in cash, cash equivalents, short-term investments and restricted cash, and no debt. This financial flexibility supports ongoing commercialization, pipeline development and potential strategic opportunities.

Analysts largely viewed the results positively. The beat on both top and bottom lines, combined with the guidance raise, validated Glaukos’ growth trajectory amid a competitive ophthalmology landscape. Several firms noted the accelerating iDose TR ramp as a key positive, with real-world physician feedback highlighting the implant’s ease of use and clinical benefits.

The glaucoma market represents a significant opportunity. With millions of patients worldwide requiring ongoing treatment, therapies that improve adherence and outcomes carry substantial commercial potential. Glaukos’ pipeline also includes candidates for corneal disorders and retinal diseases, providing longer-term diversification.

Challenges remain. The company continues to invest heavily in commercial infrastructure, clinical trials and manufacturing scale-up for iDose TR. Competition from established pharmaceutical eye-drop makers and other device players persists. Reimbursement dynamics and physician training curves can influence adoption rates.

Advertisement

Still, momentum appears firmly positive. Recent regulatory wins, including a permanent J-code for its Epioxa corneal cross-linking therapy, further bolster the portfolio. Glaukos has positioned itself as a leader in “interventional ophthalmology,” blending devices, drugs and sustained-delivery platforms.

Wall Street consensus price targets have trended higher in recent months, with several analysts maintaining Buy or Outperform ratings. The raised guidance places Glaukos on track for roughly 25-30% growth in 2026, a pace that could support further multiple expansion if execution remains strong.

For investors, Thursday’s rally underscores Glaukos’ transition from a micro-invasive glaucoma surgery pioneer to a broader ophthalmic platform company. The iDose TR launch has been a pivotal catalyst, shifting revenue mix and demonstrating the company’s ability to commercialize innovative therapies at scale.

Looking ahead, management will provide more color on the Q1 conference call and future catalysts. Key focus areas include international iDose TR expansion, pipeline progress in retina and cornea, and margin trends as volumes grow. The company’s May investor events or scientific presentations could offer additional visibility.

Advertisement

Broader sector dynamics also favor Glaukos. Aging populations drive demand for eye care, while innovation in drug delivery and surgical techniques addresses unmet needs. Glaukos’ cash position and debt-free status provide a competitive advantage in funding R&D and acquisitions.

Risks include slower-than-expected adoption curves, regulatory hurdles for new indications, and macroeconomic pressures on elective procedures. Yet the first-quarter results and guidance increase suggest Glaukos is navigating these challenges effectively.

As the stock consolidated some of Thursday’s gains, the narrative around Glaukos has clearly shifted toward growth. From its roots in tiny stents to sustained-release implants, the company continues to push boundaries in preserving vision for patients worldwide.

For a medical technology firm in a specialized field, delivering consistent beats while raising guidance is a powerful combination. Thursday’s market reaction reflects investor belief that Glaukos is entering a new phase of scaled commercialization and innovation leadership in ophthalmology.

Advertisement
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai AI Platform for Rare Cancer Drug Discovery Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Craig Brelsford

Hi. This is Craig Brelsford with RedChip Companies. Thank you for joining us for what promises to be an exciting session with Lantern Pharma. Today’s session is centered around a live real-time demonstration of withZeta.ai, Lantern Pharma’s next-generation AI platform designed to transform how oncology drugs are discovered, particularly in rare cancers. Rather than just talking about the technology, you’ll see it in action, executing research workflows, synthesizing complex scientific data and generating insights in real-time. This is a rare opportunity to observe how AI is being applied at the front lines of drug development.

Lantern Pharma, which trades on the NASDAQ under the ticker LTRN, is positioning this platform not only as a scientific engine, but also as a scalable subscription-based business with meaningful commercial potential.

Joining us today is Panna Sharma, Chief Executive Officer, President and Director of Lantern Pharma, who will guide us through the demonstration and discuss the broader implications of this technology. We will begin with the presentation and demo momentarily followed by a Q&A session. [Operator Instructions]

Advertisement

Before we begin, please allow me to read the safe harbor statement. This call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, along with other statements about the future expectations, beliefs, goals, plans or prospects expressed by management constitute forward-looking statements. Any statements that are not historical facts should also be considered forward-looking statements. And of course, forward-looking statements involve risks and uncertainties.

Panna, go right ahead.

Advertisement
Continue Reading

Business

Perth home values lift, but show signs of slowing

Published

on

Perth home values lift, but show signs of slowing

Cotality’s latest home value index shows that Perth added more than $21,000 to its median home value in April.

Continue Reading

Business

Start Hamstring Rehab Enters Key On-Court Phase as Lakers Push for Playoff Survival

Published

on

Luka Doncic

LOS ANGELES — Nearly four weeks after suffering a Grade 2 left hamstring strain, Los Angeles Lakers superstar Luka Doncic continues a cautious rehabilitation protocol focused on controlled on-court movement and progressive loading, with no firm timetable for return as the team battles through its first-round playoff series against the Houston Rockets.

Luka Doncic
Luka Doncic

The Slovenian guard, who injured his hamstring late in a blowout loss to the Oklahoma City Thunder on April 2, remains listed as out indefinitely. Coach JJ Redick confirmed this week that Doncic has advanced beyond standstill drills to light on-court activity, marking a significant step in his recovery from the partial muscle tear.

Medical experts describe a Grade 2 hamstring strain as involving noticeable fiber disruption without a complete rupture, typically requiring four to six weeks for full recovery. Doncic’s aggressive approach included traveling to Madrid shortly after the injury for specialized regenerative treatments, including platelet-rich plasma and stem cell injections under the care of physicians linked to his former club, Real Madrid.

Those interventions aimed to accelerate healing, potentially compressing the standard timeline. As of late April, sports medicine specialists like Dr. Jesse Morse estimated a possible return window of 10 to 14 days from the point when meaningful on-court movement begins, placing a potential comeback in mid-to-late May if progress holds.

Redick provided the most recent public update, noting Doncic “was able to move today a little bit on the court. Most of the stuff has been standstill. He’s progressing.” The coach stressed there is still no timeline, echoing reports from ESPN’s Shams Charania that the recovery path remains slow. Doncic has not yet progressed to one-on-one work or full-speed scrimmaging.

Advertisement

The protocol follows a standard phased return-to-play model for hamstring injuries in elite athletes. Phase one emphasized protection and controlled mobility, including rest, compression, physical therapy and the European injections. Phase two has introduced light jogging, directional changes and basketball-specific movements at sub-maximal effort. Subsequent phases will incorporate sprinting, jumping, cutting and contact before clearance for game play.

Lakers medical staff monitor metrics such as muscle strength symmetry, flexibility and pain-free range of motion. Hamstring strains carry high re-injury risk — often 20-30% in professional sports — if athletes return prematurely, particularly in a high-usage player like Doncic who relies on explosive first steps and deceleration.

Doncic rejoined the team in Los Angeles ahead of the playoffs but has not traveled with the squad for road games against Houston. His presence on the bench has provided intangible leadership, yet the Lakers have leaned heavily on LeBron James, Austin Reaves (also recovering from an oblique strain) and supporting cast members.

Expectations point to Doncic missing the entire first-round series. Even if the Lakers advance, multiple reports indicate he is unlikely to be available for the start of the Western Conference semifinals, with a more realistic target around Games 3 or 4 of a potential second-round matchup. Six weeks from the April 2 injury date would land in mid-May.

Advertisement

The injury occurred at a critical juncture. Doncic had been playing at an MVP-caliber level, powering the Lakers to a strong late-season surge. His absence has reshaped playoff dynamics in the Western Conference, forcing Los Angeles to adapt without its primary playmaker and leading scorer.

Team officials and medical experts weigh the long-term risks against short-term playoff ambitions. Rushing a return could jeopardize Doncic’s availability for future seasons or lead to chronic issues. Hamstring injuries have historically sidelined stars for extended periods, with re-aggravation often extending timelines significantly.

Doncic’s work ethic and competitive drive have been highlighted throughout the process. Sources describe him attacking rehab aggressively while remaining in good spirits. His agent, Bill Duffy, confirmed the European trip was a collaborative decision involving Lakers doctors and independent specialists.

Broader implications extend to the Lakers’ roster construction and future planning. The team traded for Doncic earlier in the season in a blockbuster move, banking on his superstar talent to elevate the franchise. His prolonged absence tests depth and underscores the fragility of championship contention when key pieces go down.

Advertisement

Fans and analysts track every update closely. Social media buzzes with speculation about potential return dates, fueled by optimistic interpretations of practice footage and vague coaching comments. Yet insiders maintain patience is essential.

For a 27-year-old in his prime, full recovery remains highly probable with proper management. Modern sports medicine, including the biologics Doncic received, has improved outcomes for soft-tissue injuries. Strength and conditioning programs tailored to basketball movements will play a pivotal role in the final rehab stages.

As the Lakers navigate the playoffs without their All-NBA talent, focus shifts to collective resilience. James has shouldered a heavier load, while younger players step into expanded roles. A deep run without Doncic would be impressive; his eventual return could provide a massive boost for later rounds.

Looking ahead, the Lakers’ medical staff will continue daily assessments. Progression to non-contact 3-on-3 or 5-on-5 work will signal the next major milestone. Only after clearing sport-specific testing, including sprint times and change-of-direction drills, will Doncic receive medical clearance.

Advertisement

The organization emphasizes a conservative approach. “We’re going to do what’s best for Luka long-term,” Redick has reiterated in various forms. That philosophy prioritizes sustainable health over rushed availability.

Doncic’s injury serves as a reminder of basketball’s physical demands. Even superstars face setbacks, and recovery protocols balance science, patience and individual response. For now, the focus remains on incremental gains — more fluid movement, greater confidence in the hamstring and steady buildup toward basketball activities.

Whether Doncic returns this postseason or begins the 2026-27 season fully healthy, his current protocol reflects best practices in elite athlete care. The basketball world watches, hoping the star’s dedication yields a strong comeback when the moment is right.

Advertisement
Continue Reading

Business

Senseonics prices $80 million public offering at $5 per share

Published

on


Senseonics prices $80 million public offering at $5 per share

Continue Reading

Business

Karlka Nyiyaparli Aboriginal Corporation to build Swan Valley hub for Perth medical travel

Published

on

Karlka Nyiyaparli Aboriginal Corporation to build Swan Valley hub for Perth medical travel

A Pilbara native title group is building a home away from home in Perth to house traditional owners visiting the city for medical treatment.

Continue Reading

Business

China scraps tariffs for all but one African nation

Published

on

China scraps tariffs for all but one African nation

The zero-tariff regime gives China’s soft power a boost, but may lead to uneven gains, say analysts.

Continue Reading

Business

Trump lifts Scotch whisky tariffs after King Charles’ state visit

Published

on

Trump lifts Scotch whisky tariffs after King Charles' state visit

President Trump announced Thursday he was removing tariffs on Scotch whisky after a four-day British royal state visit to the United States, crediting King Charles III and Queen Camilla.

As he often does, Trump announced the move on Truth Social.

Advertisement

“The King and Queen got me to do something that nobody else was able to do, without hardly even asking!” he wrote. “In Honor of the King and Queen of the United Kingdom, who have just left the White House, soon headed back to their wonderful Country, I will be removing the Tariffs and Restrictions on Whisky.”

FEDERAL RESERVE LEAVES INTEREST RATES UNCHANGED AS POWELL’S CHAIRMANSHIP NEARS END

Queen Camilla King Charles III President Donald Trump and First Lady Melania Trump posing on the South Lawn of the White House

Queen Camilla, King Charles III, U.S. President Donald Trump, and first lady Melania Trump pose during a state arrival ceremony on the South Lawn of the White House on April 28, 2026, in Washington, D.C. (Chip Somodevilla/Getty Images / Getty Images)

The removal affects restrictions “on Whiskey having to do with Scotland’s ability to work with the Commonwealth of Kentucky on Whisky and Bourbon, two very important industries within Scotland and Kentucky,” he added.

Trump said people have been asking for the change. However, his announcement was unclear as to whether the tariff removal applied to bottles of Scotch or on the materials used to produce alcohol in both the United States and Scotland.

Advertisement

Fox News Digital has reached out to the White House for comment.

In 2025, the U.S. and the United Kingdom signed a deal allowing Washington to impose a 10% baseline tariff on imports of most British goods, part of an effort by Trump to correct what he perceived as long-standing trade imbalances.

AIR CANADA SCRAPS KEY US ROUTES AS FUEL COSTS SURGE AMID IRAN CONFLICT

jameson bottles on shelves

Jameson and Powers whisky for sale at a supermarket as a new minimum price increase for alcohol is implemented in Galway, Ireland, Jan. 4, 2022. (Clodagh Kilcoyne/File Photo / Reuters)

While speaking to reporters in the Oval Office, Trump said the tariffs were lifted to enhance the trade of barrels between Scotland and Kentucky, which produces almost all the world’s bourbon. The barrels are used to age the alcohol, The Associated Press reported.

Advertisement

John Swinney, Scotland’s first minister, praised the removal, calling it a “tremendous success” for his country. 

“People’s jobs were at stake. Millions of pounds were being lost every month from the Scottish economy,” he said.

Chris Swonger, the president and CEO of the Distilled Spirits Council, called Trump’s announcement a “major victory” for American hospitality businesses that are deeply impacted by international trade.

“The United States and the United Kingdom share a deep and enduring spirits tradition built on generations of craftsmanship, agriculture and market access,” he said in a statement. “We applaud President Trump for working to restore a proven zero-for-zero model of fair, reciprocal trade between our two nations.”

Advertisement

CLICK HERE TO GET FOX BUSINESS ON THE GO

Swonger said the move “strengthens transatlantic ties” and brings “much-needed certainty to our industry,” allowing spirits producers on both sides of the Atlantic to grow, invest and support jobs at a critical time.

Advertisement
Continue Reading

Business

Tech Investors’ Earning Day Wish: No New Spending Sprees

Published

on

Heather Gillers hedcut

Traders are gearing up for Wall Street’s “Super Bowl” Wednesday when tech giants Alphabet, Amazon, Meta and Microsoft will all share their latest quarterly results. Investors will have one eye on revenue growth and the other on the firms’ capital expenditures–the price tag for the firms’ massive artificial intelligence buildouts.

“Investors do not want capex getting revised higher, “ said Jed Ellerbroek, a portfolio manager at Argent Capital Management.

Continue Reading

Business

Silver And Gold Intraday Outlook: Metals Shine Bright After The FOMC Meeting

Published

on

Silver And Gold Intraday Outlook: Metals Shine Bright After The FOMC Meeting

Silver And Gold Intraday Outlook: Metals Shine Bright After The FOMC Meeting

Continue Reading

Business

What Should SMEs Look for in a Full-Service Business Law Firm?

Published

on

The UK has long been a leader in artificial intelligence (AI) research, pioneering breakthroughs in areas like healthcare, financial modelling and cybersecurity. The Government’s AI Action Plan and recent investments highlight a clear ambition to establish the UK as a global AI superpower. However, ambition alone is not enough.

Choosing the right business law firm is one of the more important decisions you will make as an SME owner. It shapes how you handle risk, manage transactions, and deal with issues as they come up.

If you want a clear way to assess your options, focus on five things:

  • Breadth of legal services under one roof
  • Commercial understanding, not just legal knowledge
  • Transparent and predictable fees
  • Relevant transaction and sector experience
  • Easy access to consistent, experienced advisers

Get these right, and everything else tends to follow.

Does the Firm Cover All the Legal Areas Your Business Needs?

Most SMEs do not deal with legal issues in isolation. Employment, contracts, property, and corporate work often overlap, sometimes within the same transaction. If your firm only covers part of that, you end up managing multiple advisers. That usually means higher costs, slower progress, and more chances for gaps.

Rubric Law provides legal services across corporate, employment, commercial, and dispute resolution, giving SMEs a single, consistent point of contact as different issues arise. This matters most when legal areas connect.

An acquisition with TUPE implications, or a business sale linked to a property transaction, needs joined-up advice. If teams are not aligned, issues tend to surface later, when they are harder and more expensive to fix.

Advertisement

When comparing firms, ask which areas they handle in-house. If work is referred out, it adds time, cost, and another layer to manage.

Does the Firm Offer Commercial Insight?

Legal accuracy should be a given. What actually makes a difference is whether the firm can explain what that legal position means for your business.

Think about it this way. You are not just asking, “Is this clause enforceable?” You are really asking, “What does this mean for me, and what should I do next?”

A good adviser will talk in terms of risk, options, and likely outcomes. They will connect the legal detail to your commercial reality.

Advertisement

You can usually spot this early. In initial conversations, pay attention to the questions they ask. A strong firm will want to understand:

  • Your business model
  • Your objectives
  • Your appetite for risk

If they skip that and go straight into technical explanation, that is often how they will approach the rest of the work.

Fixed Fee vs Hourly Billing Structure

Fees are where a lot of SME frustration comes from, usually because of uncertainty rather than the cost itself.

The billing model makes a big difference to how well you can plan:

Factor Fixed Fee Hourly Billing
Cost certainty High Low
Best suited to Defined-scope matters Complex, open-ended matters
Budget planning Predictable Harder to forecast
Overrun risk Firm carries it Client carries it

Fixed fees work well when the scope is clear, things like shareholder agreements, employment contracts, or standard conveyancing.

Advertisement

Hourly billing tends to fit situations where the scope is less predictable, such as disputes or more complex transactions.

Some firms default to hourly billing for everything. That can make routine work more expensive than it needs to be, and it makes budgeting harder than it should be.

It is worth asking a few direct questions upfront:

  • Which services are offered on a fixed fee basis?
  • Which are billed hourly?
  • Can you provide typical cost ranges for the work I am likely to need?

Clarity here saves a lot of friction later.

Does Their Transaction Experience Match Your Sector?

Not all corporate experience is equal. There is a difference between general corporate advice and hands-on transaction experience.

Advertisement

For example, a management buy-out involves specific deal structures and negotiation points. A share sale requires careful handling of disclosures, warranties, and completion processes. These are not things you want a firm learning as they go.

Sector experience matters just as much. If your business operates in a regulated space like healthcare, financial services, or food production, there are compliance requirements that directly affect how deals are structured.

A firm without that background may still get there, but it often takes longer and carries more risk.

Ask for specific examples of completed transactions in your sector and deal size. General statements about experience are less useful than real, recent examples.

Advertisement

Accessibility and Relationship Continuity

Good legal advice is only helpful if you can get it when you need it. There will be moments where something urgent comes up, a contract issue, an employee problem, or a decision that cannot wait. In those situations, slow responses are more than frustrating; they can affect outcomes.

Different firms handle this in different ways. Larger firms may introduce you to a senior partner, then pass the day-to-day work to junior team members. Smaller firms may offer a more personal service but struggle with capacity on more complex matters.

What most SMEs need is consistency. You want to know who you are dealing with, and you want that person to stay involved.

Before you instruct a firm, ask:

Advertisement
  • Who will handle my work day to day?
  • Will that person stay involved throughout?
  • What are your typical response times?

It sounds basic, but it makes a real difference once work starts.

Checklist, Questions to Ask Before Instructing a Business Law Firm

If you are comparing a few firms, these questions help you cut through the surface-level differences:

  • Which practice areas do you handle in-house, and which do you refer out?
  • Can you provide examples of work completed in my sector?
  • How do you structure fees for the type of work I need most?
  • Who will manage my matter day to day?
  • What are your standard response times?
  • How do you explain legal risk in commercial terms?
  • Have you advised businesses at my stage of growth or transaction size?

Get the Legal Support Your Business Needs

Choosing a business law firm is worth doing properly. When you take the time to assess service breadth, commercial understanding, fee clarity, experience, and accessibility, you reduce the risk of problems later.

If you are about to instruct a firm, use the checklist above and have those conversations early. It will give you a much clearer sense of whether they are the right fit for your business.

Advertisement
Continue Reading

Trending

Copyright © 2025